This article was originally published in The Gray Sheet
Executive SummaryFirm receives humanitarian use designation for its Vocare bladder system, which is intended for individuals with complete spinal cord injuries. Vocare uses functional electrical stimulation technology to deliver electrical impulses to nerve roots leading to bladder and bowel muscles, helping those with complete spinal cord injuries to control the loss of bladder and bowel functions. Since the commencement of clinical trials in mid-1996 ("The Gray Sheet" May 13, 1996, I&W-5), twenty-six people have been implanted with the device, the firm says. NeuroControl estimates approximately 73,000 people in the U.S. could potentially benefit from the product...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.